4.8 Article

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1012539107

Keywords

microfluidics; ctcs; prostate cancer; clusters; point-of-care

Funding

  1. Prostate Cancer Foundation
  2. National Institute for Biomedical Imaging and Bioengineering
  3. National Institutes of Health/National Cancer Institute (NIH)/(NCI) [CA89138]
  4. Ellison Foundation
  5. AstraZeneca
  6. Martell Foundation
  7. Alex and Sonja Spier
  8. Monell Foundation
  9. American Cancer Society New England Division
  10. NIH
  11. Department of Defense
  12. American Society of Clinical Oncology (ASCO) Cancer Foundation
  13. Howard Hughes Medical Institute

Ask authors/readers for more resources

Rare circulating tumor cells (CTCs) present in the bloodstream of patients with cancer provide a potentially accessible source for detection, characterization, and monitoring of nonhematological cancers. We previously demonstrated the effectiveness of a microfluidic device, the CTC-Chip, in capturing these epithelial cell adhesion molecule (EpCAM)-expressing cells using antibody-coated microposts. Here, we describe a high-throughput microfluidic mixing device, the herringbone-chip, or HB-Chip, which provides an enhanced platform for CTC isolation. The HB-Chip design applies passive mixing of blood cells through the generation of microvortices to significantly increase the number of interactions between target CTCs and the antibody-coated chip surface. Efficient cell capture was validated using defined numbers of cancer cells spiked into control blood, and clinical utility was demonstrated in specimens from patients with prostate cancer. CTCs were detected in 14 of 15 (93%) patients with metastatic disease (median 63 CTCs/mL, mean = 386 +/- 238 CTCs/mL), and the tumor-specific TMPRSS2-ERG translocation was readily identified following RNA isolation and RT-PCR analysis. The use of transparent materials allowed for imaging of the captured CTCs using standard clinical histopathological stains, in addition to immunofluorescence-conjugated antibodies. In a subset of patient samples, the low shear design of the HB-Chip revealed microclusters of CTCs, previously unappreciated tumor cell aggregates that may contribute to the hematogenous dissemination of cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available